1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology
  4. > Biopharmaceutical Market Trends
Biosimilars Education: Addressing a significant unmet need

Biosimilars Education: Addressing a significant unmet need

  • November 2016
  • ID: 4699256
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Description

How to educate stakeholders about biosimilar benefits

What information and data do physicians, payers and patients need about biosimilars? benefits
As the market expands and new therapeutic sectors come on stream, more stakeholders will come into contact with biosimilars. Their information needs vary widely from a basic understanding of biosimilars to detailed scientific data. What educational programmes are required and how can biosimilar developers deliver the specific messages and knowledge that give physicians and patients’ confidence? benefits

Report Overview
To help you meet the educational challenges in the US and EU, leading industry experts and KOLs share their frontline knowledge in Biosimilars Education: Addressing a significant unmet need.

Report Features
- In-depth interviews reveal unique insights from the different perspectives of industry experts and clinical KOLs in the US and EU.
- Extensive examination of US and EU biosimilar regulatory and market environments
- Tables showing approved biosimilars in EU and US.
- Chart illustrating the role of stakeholders in improving biosimilar trust and confidence.
- Chart illustrating the 5 major biosimilar knowledge gaps.
- Survey chart showing responses as to how HCP’s want to access biosimilar information.
- Chart: Biosimilar education areas of focus.
- Chart: Comparative pathways to regulatory submission for traditional and biosimilar approaches.
- At-a-glance summaries of all the main insights.

Key Benefits
- Understand the different market conditions in the established EU market and fast developing US biosimilar sector.
- Appreciate the varying levels of physician knowledge and know what that means for education programme design.
- Know what is an appropriate level of information and support for patients.
- Review the biosimilar educational initiatives of organisations such as Amgen, Pfizer, Merck and the FDA.
- Respond to the anxieties of physicians who are newly dealing with biosimilar products that lack the wealth of trial and clinical data of originator therapies.
- Develop powerful educational programmes as part of your value added services and outreach.
- Plan to expand your post-marketing monitoring and use real world knowledge to enhance your clinical education.

Key Questions Answered By This Report
- Two-speed markets: The EU and US biosimilars markets are at very different stages of their evolution – what can be learnt from these diverse experiences?
- Listen, then speak: How can listening to stakeholders about the information they want – and how they want it – help to deliver on target education?
- Clinical confidence: How can you respond to physicians’ anxieties about using a biosimilar of which they have no experience or supporting data?
- Patient Information: What level of education should patients get and who should deliver it to them?
- Trust: How can you deliver your educational messages in a way that is trusted by physicians?
- Differentiation: How can innovative educational programmes help to differentiate your biosimilar product?

Expert Views
To ensure candid views were expressed, some expert names have been kept anonymous, but each has been selected for their experience and detailed current knowledge of the biosimilar space.

Industry experts interviewed:
- Dr Bert Liang Founding CEO of Pfenex Inc, a biosimilar development company. He was previously founder, Chairman and CEO of Tracon Pharma and founder and Chairman of Coronado Biosciences.
- Dr Virginia Acha, Executive Director – Research, Medical & Innovation, Association of the British Pharmaceutical Industry. Formerly she worked for Amgen as Director, Global Regulatory and R&D Policy – EMEA and at Pfizer working on policy development in science and innovation in healthcare.
- Matthew S. Jones Chief Commercial Officer, Dyadic International Inc, where he leads their strategic partnering, licensing and commercial activities. Formerly he worked for Lonza Biologics and Ricerca BioSciences LLP.
- Senior Medical Director, Top 25 biopharmaceutical company, EU
- Global Head of Medical Affairs, Top 10 biopharmaceutical company, EU

Key opinion leaders interviewed, all of whom are specialists in oncology:
- Key Opinion Leader, UK
- Key Opinion Leader, France
- Key Opinion Leader, US

4 Key Quotes
“Realising that physicians still need more information on what the biosimilar concept is about, we shifted back to the basics. Before overwhelming them with detailed study data, we really moved back to the basics to lay the foundations of general understanding, because it is a totally different concept to what physicians are used to with a new originator drug.”
Global Head of Medical Affairs, EU Biosimilar Company

“If you've got the safety and efficacy endpoint and you are a tenth of the price of the branded product, then that's a great place to be. Now it's about carefully adding extra value, for example around engaging with patients and helping them to adhere to their prescription. We invest heavily in patient engagement programmes around adherence. We think it's a very powerful reimbursement payer discussion to have if you have data that says we support our patients taking their medicines in the way that they have been prescribed. In the modern world that equates to social media and apps for iPads, iPhones and similar devices.”
Matthew Jones, Dyadic

“The more experienced physicians become using these biosimilars, and they understand that their experience is similar to that of our European colleagues, I think that's the key component that is going to allow for driving forward these medications, because one physician will educate another one as well.”
Dr Bert Liang, Biosimilars Council

“Doctors can't spend a lot of time, so get to the point that biosimilars are different in this way; they are just as safe; they are just as efficacious; and here's the potential cost-effectiveness benefit that you get from them.”
Key Opinion Leader, US

Who Would Benefit from This Report?
- Medical affairs teams supporting biosimilar market access
- HEOR professionals building evidence of biosimilar value
- MSL teams needing to demonstrate the safety and efficacy of biosimilars to physicians
- Marketing teams using educational initiatives within a biosimilar product’s offering
- Brand teams wanting to competitively differentiate their biosimilar in the market
- Competitive intelligence professionals monitoring competitor education initiatives
Post-marketing surveillance teams collecting real world data on clinical and patient biosimilar experience

Content Highlights
Executive summary
- Background and definitions
- What are biosimilars?

Biosimilars regulation
- Europe
- United States
- Biosimilars nomenclature
- Biosimilars market environment
- Europe
- United States
- Key reference products targeted by biosimilar developers

Biosimilars Education
- Understanding the gaps in educational programmes
- Surveys highlight major knowledge gaps and a lack of trust
- The content of biosimilars education: an industry perspective
- Back to basics: what are biosimilars and are they safe? An industry perspective
- What is a biosimilar and why is it not the same as a generic? An HCP perspective
- Physicians want to understand the development process
- Educating all stakeholders, not just physicians
- Patient access and support
- Patient awareness of biosimilars: an HCP perspective

A review of biosimilars education channels
- Biosimilars CME via online channels
- Biosimilars CME from the FDA
- Company online resources
- Alliance for Safe Biologic Medicines
- Collaborative biosimilar education initiatives
- Trends in biosimilars education delivery
- An industry perspective
- KOLs expect to be educated at medical meetings
- Stakeholders becoming proactive in biosimilars education delivery
- The biosimilars education maturity curve
- The importance of tailoring education to the audience
- An opportunity for US education to build on the experience in Europe
- Biosimilars will test the science as they enter the oncology setting
- Critical success factors for biosimilar education programmes

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on